Stroke prevention: Managing modifiable risk factors

Stroke Research and Treatment

Volumn , Issue , 2012, Pages

  Di Legge, Silvia ^a   Koch, Giacomo ^a,b   Diomedi, Marina ^a   Stanzione, Paolo ^a,b   Sallustio, Fabrizio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ANGIOTENSIN II; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; CLOPIDOGREL; DABIGATRAN; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRENDIPINE; PERINDOPRIL; RAMIPRIL; RIVAROXABAN; SIMVASTATIN; TELMISARTAN; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ARTERIAL WALL THICKNESS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; ENDOTHELIAL PROGENITOR CELL; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTROPHY; INCIDENCE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION;

EID: 84870160232     PISSN: None     EISSN: 20420056     Source Type: Journal    
DOI: 10.1155/2012/391538     Document Type: Review

References (120)

1. Roger V. L., Go A. S., Lloyd-Jones D. M., Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011 123 e18 e209
2. Minino A. M., Xu J., Kochanek K. D., Deaths: Preliminary Data for 2008 2010 Hyattsville, Md, YSA National Center for Health Statistics National Vital Statistics Reports, Vol. 59, No. 2. http://www.cdc.gov/nchs/data/nvsr/nvsr59/ nvsr5902.pdf
3. Prevalence of disabilities and associated health conditions among adults-United states, 1999. Morbidity and Mortality Weekly Report 2001 50 7 120 125 2-s2.0-0035962091
4. Opara J. A., Jaracz K., Quality of life of post-stroke patients and their caregivers. Journal of Medicine and Life 2010 3 3 216 220 2-s2.0-79952044201
5. Carandang R., Seshadri S., Beiser A., Kelly-Hayes M., Kase C. S., Kannel W. B., Wolf P. A., Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA 2006 296 24 2939 2946 2-s2.0-33845866055 10.1001/jama.296.24.2939 (Pubitemid 46023453)
6. Feigin V. L., Lawes C. M., Bennett D. A., Barker-Collo S. L., Parag V., Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. The Lancet Neurology 2009 8 4 355 369 2-s2.0-62149099593 10.1016/S1474-4422(09)70025-0
7. Hachinski V., Donnan G. A., Gorelick P. B., Hacke W., Cramer S. C., Kaste M., Fisher M., Brainin M., Buchan A. M., Lo E. H., Skolnick B. E., Furie K. L., Hankey G. J., Kivipelto M., Morris J., Rothwell P. M., Sacco R. L., Smith S. C., Wang Y., Bryer A., Ford G. A., Iadecola C., Martins S. C. O., Saver J., Skvortsova V., Bayley M., Bednar M. M., Duncan P., Enney L., Finklestein S., Jones T. A., Kalra L., Kleim J., Nitkin R., Teasell R., Weiller C., Desai B., Goldberg M. P., Heiss W. D., Saarelma O., Schwamm L. H., Shinohara Y., Trivedi B., Wahlgren N., Wong L. K., Hakim A., Norrving B., Prudhomme S., Bornstein N. M., Davis S. M., Goldstein L. B., Leys D., Tuomilehto J., Stroke: working toward a prioritized world agenda. International Journal of Stroke 2010 5 4 238 256 2-s2.0-77955134515 10.1111/j.1747-4949.2010.00442.x
8. Furie K. L., Kasner S. E., Adams R. J., Albers G. W., Bush R. L., Fagan S. C., Halperin J. L., Johnston S. C., Katzan I., Kernan W. N., Mitchell P. H., Ovbiagele B., Palesch Y. Y., Sacco R. L., Schwamm L. H., Wassertheil-Smoller S., Turan T. N., Wentworth D., Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American stroke association. Stroke 2011 42 1 227 276 2-s2.0-79451474588 10.1161/STR.0b013e3181f7d043
9. Johnston S. C., Gress D. R., Browner W. S., Sidney S., Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000 284 22 2901 2906 2-s2.0-0034645547
10. Cushman W. C., Evans G. W., Byington R. P., Goff D. C. Jr., Grimm R. H., Cutler J. A., Simons-Morton D. G., Basile J. N., Corson M. A., Probstfield J. L., Katz L., Peterson K. A., Friedewald W. T., Buse J. B., Bigger J. T., Gerstein H. C., Ismail-Beigi F., Effects of intensive blood-pressure control in type 2 diabetes mellitus. The New England Journal of Medicine 2010 362 17 1575 1585 2-s2.0-77951735232 10.1056/NEJMoa1001286
11. Vermeer S. E., Sandee W., Algra A., Koudstaal P. J., Kappelle L. J., Dippel D. W. J., Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke 2006 37 6 1413 1417 2-s2.0-33745161513 10.1161/01.STR.0000221766.73692.0b (Pubitemid 44305718)
12. Wolf P. A., Abbott R. D., Kannel W. B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991 22 8 983 988 2-s2.0-0025779484
13. Elijovich L., Josephson S. A., Fung G. L., Smith W. S., Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. Journal of Stroke and Cerebrovascular Diseases 2009 18 3 185 189 2-s2.0-65449189576 10.1016/j.jstrokecerebrovasdis.2008.09.005
14. Curb J. D., Abbott R. D., Rodriguez B. L., Masaki K. H., Chen R., Popper J. S., Petrovitch H., Ross G. W., Schatz I. J., Belleau G. C., Yano K., High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu Heart Program. American Journal of Epidemiology 2004 160 2 150 157 2-s2.0-3242740195 10.1093/aje/kwh177 (Pubitemid 38963001)
15. Salaycik K. J., Kelly-Hayes M., Beiser A., Nguyen A. H., Brady S. M., Kase C. S., Wolf P. A., Depressive symptoms and risk of stroke: the Framingham study. Stroke 2007 38 1 16 21 2-s2.0-33845938439 10.1161/01.STR.0000251695. 39877.ca (Pubitemid 46035600)
16. Whitlock R. P., Sun J. C., Fremes S. E., Rubens F. D., Teoh K. H., Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012 141 2, supplement e576S e600S 2-s2.0-84859487422 10.1378/chest.11-2305
17. Furie K. L., Goldstein L. B., Albers G. W., Khatri P., Neyens R., Turakhia M. P., Turan T. N., Wood K. A., On behalf of the American Heart Association Stroke Council, Council on Quality of Care and Outcomes Research, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: a Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2012 43
18. Collins R., Peto R., MacMahon S., Hebert P., Fiebach N. H., Eberlein K. A., Godwin J., Qizilbash N., Taylor J. O., Hennekens C. H., Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. The Lancet 1990 335 8693 827 838 2-s2.0-0025347391 10.1016/0140-6736(90)90944-Z (Pubitemid 20113741)
19. Probstfield J. L., Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991 265 24 3255 3264 2-s2.0-0025831464 10.1001/jama.265.24.3255
20. Staessen J. A., Fagard R., Thijs L., Celis H., Arabidze G. G., Birkenhäger W. H., Bulpitt C. J., De Leeuw P. W., Dollery C. T., Fletcher A. E., Forette F., Leonetti G., Nachev C., O' Brien E. T., Rosenfeld J., Rodicio J. L., Tuomilehto J., Zanchetti A., Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet 1997 350 9080 757 764 2-s2.0-0343487983 10.1016/S0140-6736(97)05381-6 (Pubitemid 27387202)
21. Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., De Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L. H., Nieminen M. S., Omvik P., Oparil S., Wedel H., Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 2002 359 9311 995 1003 2-s2.0-0037160968 10.1016/S0140-6736(02)08089-3 (Pubitemid 34286536)
22. Chen N., Zhou M., Yang M., Guo J., Zhu C., Yang J., Wang Y., Yang X., He L., Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database of Systematic Reviews 2010 8 CD003654 2-s2.0-77955930796
23. MacMahon S., Neal B., Tzourio C., Rodgers A., Woodward M., Cutler J., Anderson C., Chalmers J., Ohkubo T., Bouser M. G., Davis S., Donnan G., Hansson L., Harrap S., Lees K. R., Liu L., Mancia G., Neal B., Omae T., Reid J., Rodgers A., Sega R., Terent A., Tzourio C., Warlow C., Woodward M., Anderson N., Bladin C., Chambers B., Gordon G., Sharpe N., Collins R., Sandercock P., Simes J., Sleight P., Brnabic A., Colman S., Francis L., Lee A., Gong L., Bousser M.-G., Yamaguchi T., Lees K. R., William F., Deng Q., Hu D. X., Wang W., Wu A. L., Ma L. Y., Tao Z. Y., Biousse V., Berthet K., Ben Slamia L., Le Denmat C., Crespi S., Foglia G., Fujimoto C., Matsumura S., Marttala K., Pettersson M., Safwenberg M., Fenton J., McIlvenna Y., Currie R., Bartram H., Briad J., Clague A., Cleverly Y., Cosson M., Culpan A., Douglas D., Flett S., Gray B., Holloway T., Milne A., Prasad R., Ratnasabapathy Y., Santos A., Wills M., Agnew T., Chapman N., Lewis N., Mullane B., Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet 2001 358 9287 1033 1041 2-s2.0-0037096702 10.1016/S0140-6736(01)06178-5 (Pubitemid 32925123)
24. Bosch J., Yusuf S., Pogue J., Sleight P., Lonn E., Rangoonwala B., Davies R., Ostergren J., Probstfield J., Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002 324 7339 699 702 2-s2.0-0037160928 (Pubitemid 34259143)
25. Diener H. C., Sacco R., Yusuf S., Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes trial (PRoFESS). Cerebrovascular Diseases 2007 23 5-6 368 380 2-s2.0-34147143086 10.1159/000100105 (Pubitemid 46742325)
26. Teo K. K., Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal 2004 148 1 52 61 2-s2.0-3142740224 10.1016/j.ahj.2004.03.020 (Pubitemid 38906646)
27. Diener H. C., Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. Journal of Hypertension 2009 27 5 S31 S36 2-s2.0-70349406414 10.1097/01.hjh.0000357906.60778.7f
28. Schrader J., Lüders S., Kulschewski A., Hammersen F., Plate K., Berger J., Zidek W., Dominiak P., Diener H. C., Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005 36 6 1218 1224 2-s2.0-20444427156 10.1161/01.STR.0000166048.35740.a9 (Pubitemid 40798742)
29. Force T., Kuida K., Namchuk M., Parang K., Kyriakis J. M., Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation 2004 109 10 1196 1205 2-s2.0-1642412825 10.1161/01.CIR.0000118538.21306.A9 (Pubitemid 38372775)
30. Verdecchia P., Gentile G., Angeli F., Reboldi G., Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Therapeutic Advances in Cardiovascular Disease 2012 6 2 81 91 2-s2.0-84860800308 10.1177/1753944712444866
31. Singer D. E., Albers G. W., Dalen J. E., Fang M. C., Go A. S., Halperin J. L., Lip G. Y. H., Manning W. J., Antithrombotic therapy in atrial fibrillation: american College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 133 6, supplement 546S 592S 2-s2.0-45949095568 10.1378/chest.08-0678 (Pubitemid 351892972)
32. Connolly S. J., Pogue J., Hart R. G., Hohnloser S. H., Pfeffer M., Chrolavicius S., Yusuf S., Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England Journal of Medicine 2009 360 20 2066 2078 2-s2.0-65649145705 10.1056/NEJMoa0901301
33. Van Latum J. C., Vermeulen P. C., Den Ouden A., Mast B., Koudstaal P. J., Bogousslavsky J., Boysen G., Bornstein N., Candelise L., Dahl T., Dehaene I., Ferro J., Van Gijn J., Gustafsson C., Hedenus M., Hijdra A., Kramer G., Lodder J., Mas J. L., Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. The Lancet 1993 342 8882 1255 1262 2-s2.0-0027505093 (Pubitemid 23338782)
34. Aguilar M. I., Hart R., Pearce L. A., Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews 2007 3 CD006186 2-s2.0-35348828077
35. Akins P. T., Feldman H. A., Zoble R. G., Newman D., Spitzer S. G., Diener H. C., Albers G. W., Wentworth D., Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke 2007 38 3 874 880 2-s2.0-33947491766 10.1161/01.STR.0000258004.64840.0b (Pubitemid 46568446)
36. Halperin J. L., Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005 293 6 690 698 2-s2.0-13444309949 10.1001/jama.293.6.690 (Pubitemid 40220342)
37. Connolly S. J., Ezekowitz M. D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P. A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., Lewis B. S., Darius H., Diener H. C., Joyner C. D., Wallentin L., Alings A. M. W., Amerena J. V., Avezum A., Baumgartner I., Brugada J., Budaj A., Caicedo V., Ceremuzynski L., Chen J. H., Commerford P. J., Connolly S. J., Dans A. L., Darius H., Di Pasquale G., Diaz R., Erol C., Ezekowitz M. D., Ferreira J., Flaker G. C., Flather M. D., Franzosi M. G., Gamboa R., Golitsyn S. P., Gonzalez Hermosillo J. A., Halon D., Heidbuchel H., Hohnloser S. H., Hori M., Huber K., Jansky P., Kamensky G., Keltai M., Kim S., Lau C. P., Le Heuzey J. Y. F., Lewis B. S., Liu L. S., Nanas J., Oldgren J., Pais P. S., Parkhomenko A. N., Pedersen K. E., Piegas L. S., Raev D., Razali O., Simmers T. A., Smith P. J., Talajic M., Tan R. S., Tanomsup S., Toivonen L., Vinereanu D., Wallentin L., Xavier D., Yusuf S., Zhu J., Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2009 361 12 1139 1151 2-s2.0-70349306707 10.1056/NEJMoa0905561
38. Patel M. R., Mahaffey K. W., Garg J., Pan G., Singer D. E., Hacke W., Breithardt G., Halperin J. L., Hankey G. J., Piccini J. P., Becker R. C., Nessel C. C., Paolini J. F., Berkowitz S. D., Fox K. A. A., Califf R. M., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine 2011 365 10 883 891 2-s2.0-84856173585 10.1056/NEJMoa1009638
39. Granger C. B., Alexander J. H., McMurray J. J. V., Lopes R. D., Hylek E. M., Hanna M., Al-Khalidi H. R., Ansell J., Atar D., Avezum A., Bahit M. C., Diaz R., Easton J. D., Ezekowitz J. A., Flaker G., Garcia D., Geraldes M., Gersh B. J., Golitsyn S., Goto S., Hermosillo A. G., Hohnloser S. H., Horowitz J., Mohan P., Jansky P., Lewis B. S., Lopez-Sendon J. L., Pais P., Parkhomenko A., Verheugt F. W. A., Zhu J., Wallentin L., Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2011 365 11 981 992 2-s2.0-82655183578 10.1056/NEJMoa1107039
40. Connolly S. J., Eikelboom J., Joyner C., Diener H. C., Hart R., Golitsyn S., Flaker G., Avezum A., Hohnloser S. H., Diaz R., Talajic M., Zhu J., Pais P., Budaj A., Parkhomenko A., Jansky P., Commerford P., Tan R. S., Sim K. H., Lewis B. S., Van Mieghem W., Lip G. Y. H., Kim J. H., Lanas-Zanetti F., Gonzalez-Hermosillo A., Dans A. L., Munawar M., O'Donnell M., Lawrence J., Lewis G., Afzal R., Yusuf S., Apixaban in patients with atrial fibrillation. The New England Journal of Medicine 2011 364 9 806 817 2-s2.0-79952301326 10.1056/NEJMoa1007432
41. Miller C. S., Grandi S. M., Shimony A., Filion K. B., Eisenberg M. J., Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. American Journal of Cardiology 2012 110 3 453 460 2-s2.0-84865319303 10.1016/j.amjcard.2012.03.049
42. Agarwal S., Hachamovitch R., Menon V., Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Archives of Internal Medicine 2012 172 8 623 631 2-s2.0-84860372565 10.1001/archinternmed.2012.121
43. Qizilbash N., Lewington S., Duffy S., Peto R., Cholesterol, diastolic blood pressure, and stroke: 13, 000 strokes in 450, 000 people in 45 prospective cohorts. The Lancet 1995 346 8991-8992 1647 1653 2-s2.0-0029557105 (Pubitemid 26003320)
44. Pedersen T. R., Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet 1994 344 8934 1383 1389 2-s2.0-0027987849 (Pubitemid 24365311)
45. Collins R., Armitage J., Parish S., Sleight P., Peto R., MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. The Lancet 2002 360 9326 7 22 2-s2.0-0037031061 10.1016/S0140-6736(02)09327-3 (Pubitemid 34756487)
46. Straus S. E., Majumdar S. R., McAlister F. A., New evidence for stroke prevention: scientific review. JAMA 2002 288 11 1388 1395 2-s2.0-0037130648 (Pubitemid 35025911)
47. Amarenco P., Bogousslavsky J., Callahan A., Goldstein L. B., Hennerici M., Rudolph A. E., Sillesen H., Simunovic L., Szarek M., Welch K. M. A., Zivin J. A., High-dose atorvastatin after stroke or transient ischemic attack. The New England Journal of Medicine 2006 355 6 549 559 2-s2.0-33746895436 10.1056/NEJMoa061894 (Pubitemid 44202151)
48. Amarenco P., Labreuche J., Lavallée P., Touboul P. J., Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004 35 12 2902 2909 2-s2.0-9444249842 10.1161/01.STR.0000147965.52712.fa (Pubitemid 39565192)
49. Massaro M., Zampolli A., Scoditti E., Carluccio M. A., Storelli C., Distante A., De Caterina R., Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovascular Research 2010 86 2 311 320 2-s2.0-77950008071 10.1093/cvr/cvp375
50. Zhang Y., Tuomilehto J., Jousilahti P., Wang Y., Antikainen R., Hu G., Total and high-density lipoprotein cholesterol and stroke risk. Stroke 2012 43 7 1768 1774 2-s2.0-84863324881 10.1161/STROKEAHA.111.646778
51. Mikhailidis D. P., Sibbring G. C., Ballantyne C. M., Davies G. M., Catapano A. L., Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Current Medical Research and Opinion 2007 23 8 2009 2026 2-s2.0-34548125027 10.1185/030079907X210507 (Pubitemid 47300401)
52. Angelopoulos J., Krassakopoulos N., Nathanson R., Boukas S., Sampalis J. S., Co-administration of ezetimibe and a statin in management of dyslipidemias: a meta-analysis of clinical trials. Archives of Medical Science 2009 5 3 347 363 2-s2.0-73449112615
53. Briel M., Ferreira-Gonzalez I., You J. J., Karanicolas P. J., Akl E. A., Wu P., Blechacz B., Bassler D., Wei X., Sharman A., Whitt I., Da Silva S. A., Khalid Z., Nordmann A. J., Zhou Q., Walter S. D., Vale N., Bhatnagar N., O'Regan C., Mills E. J., Bucher H. C., Montori V. M., Guyatt G. H., Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009 338, article b92 2-s2.0-61749104449 10.1136/bmj.b92
54. Ridker P. M., Genest J., Boekholdt S. M., Libby P., Gotto A. M., Nordestgaard B. G., Mora S., MacFadyen J. G., Glynn R. J., Kastelein J. J. P., HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. The Lancet 2010 376 9738 333 339 2-s2.0-77955712458 10.1016/S0140-6736(10)60713-1
55. Lukovits T. G., Mazzone T., Gorelick P. B., Diabetes mellitus and cerebrovascular disease. Neuroepidemiology 1999 18 1 1 14 2-s2.0-0032890150 10.1159/000026190 (Pubitemid 28550756)
56. Sacco R. L., Foulkes M. A., Mohr J. P., Wolf P. A., Hier D. B., Price T. R., Determinant so early recurrence of cerebral infarction: the Stroke Data Bank. Stroke 1989 20 8 983 989 2-s2.0-0024472711 (Pubitemid 19204008)
57. Hier D. B., Foulkes M. A., Swiontoniowski M., Sacco R. L., Gorelick P. B., Mohr J. P., Price T. R., Wolf P. A., Stroke recurrence within 2 years after ischemic infarction. Stroke 1991 22 2 155 161 2-s2.0-0025975917
58. Cunningham E. J., Bond R., Mehta Z., Mayberg M. R., Warlow C. P., Rothwell P. M., Long-term durability of carotid endarterectomy for symptomatic stenosis and risk factors for late postoperative stroke. Stroke 2002 33 11 2658 2663 2-s2.0-0036844048 10.1161/01.STR.0000034397.72390.D3 (Pubitemid 35266438)
59. Turner R., Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998 352 9131 837 853 2-s2.0-0032511583 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
60. Gerstein H. C., Yusuf S., Mann J. F. E., Hoogwerf B., Zinman B., Held C., Fisher M., Wolffenbuttel B., Bosch J., Richardson L., Pogue J., Halle J.-P., Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet 2000 355 9200 253 259 2-s2.0-0034596511 10.1016/S0140-6736(99)12323-7 (Pubitemid 30068516)
61. Callahan A., Amarenco P., Goldstein L. B., Sillesen H., Messig M., Samsa G. P., Altafullah I., Ledbetter L. Y., MacLeod M. J., Scott R., Hennerici M., Zivin J. A., Welch K. M. A., Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Archives of Neurology 2011 68 10 1245 1251 2-s2.0-80053917726 10.1001/archneurol.2011.146
62. Friedewald W. T., Buse J. B., Bigger J. T., Byington R. P., Cushman W. C., Gerstein H. C., Ginsberg H. N., Goff D. C., Grimm R. H., Ismail-Beigi F., Probstfield J. L., Simons-Morton D. G., Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine 2008 358 24 2545 2559 2-s2.0-45149131667 10.1056/NEJMoa0802743 (Pubitemid 351831356)
63. Chalmers J., Cooper M., Ferrannini E., Glasziou P., Grobbee D., Hamet P., Harrap S., Liu L., MacMahon S., Mancia G., Marre M., Matthews D., Mogensen C., Neal B., Yu Pan C., Poulter N., Rodgers A., Williams B., Woodward M., Collins R., Sandercock P., Sleight P., Holman R., Fulcher G., Pollock C., Celermajer D., Watson J., Harrisberg B., Currie R., Girgis S., Jayne K., Monaghan H., Patel A., Richens A., Gray B., Milne A., Adderkin A., Bak A., Flett S., De Guise D., Jetses E., Reid J., Stolk R., Wang W., Williams F., Zou X., Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia 2001 44 9 1118 1120 2-s2.0-17944382481 10.1007/s001250100612 (Pubitemid 32835503)
64. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P. D., Zieve F. J., Marks J., Davis S. N., Hayward R., Warren S. R., Goldman S., McCarren M., Vitek M. E., Henderson W. G., Huang G. D., Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine 2009 360 2 129 139 2-s2.0-58149389215 10.1056/NEJMoa0808431
65. Wilcox R., Bousser M. G., Betteridge D. J., Schernthaner G., Pirags V., Kupfer S., Dormandy J., Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 38 3 865 873 2-s2.0-33947539408 10.1161/01.STR.0000257974.06317.49 (Pubitemid 46568445)
66. Executive summary: standards of medical care in diabetes-2009. Diabetes Care 2009 32 supplement 1 S6 12 2-s2.0-63149173251
67. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003 289 19 2560 2572 2-s2.0-0038460302 10.1001/jama.289.19.2560 (Pubitemid 37430158)
68. Antithrombotic Trialists' (ATT) Collaboration, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet 2009 373 9678 1849 1860 2-s2.0-65849268320 10.1016/S0140-6736(09)60503-1
69. Gent M., A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 1996 348 9038 1329 1339 2-s2.0-0030590746 10.1016/S0140-6736(96)09457-3 (Pubitemid 26383772)
70. Diener P. H. C., Bogousslavsky P. J., Brass P. L. M., Cimminiello P. C., Csiba P. L., Kaste P. M., Leys P. D., Matias-Guiu P. J., Rupprecht P. H. J., Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. The Lancet 2004 364 9431 331 337 2-s2.0-3242770664 10.1016/S0140-6736(04)16721-4 (Pubitemid 38970009)
71. Bhatt D. L., Fox K. A. A., Hacke W., Berger P. B., Black H. R., Boden W. E., Cacoub P., Cohen E. A., Creager M. A., Easton J. D., Flather M. D., Haffner S. M., Hamm C. W., Hankey G. J., Johnston S. C., Mak K. H., Mas J. L., Montalescot G., Pearson T. A., Steg P. G., Steinhubl S. R., Weber M. A., Brennan D. M., Fabry-Ribaudo L., Booth J., Topol E. J., Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England Journal of Medicine 2006 354 16 1706 1717 2-s2.0-33645861080 10.1056/NEJMoa060989
72. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. The Lancet 2006 367 9523 1665 1673 2-s2.0-33646596912 10.1016/S0140-6736(06)68734-5 (Pubitemid 43728258)
73. Sacco R. L., Diener H. C., Yusuf S., Cotton D., Ôunpuu S., Lawton W. A., Palesch Y., Martin R. H., Albers G. W., Bath P., Bornstein N., Chan B. P. L., Chen S. T., Cunha L., Dahlöf B., De Keyser J., Donnan G. A., Estol C., Gorelick P., Gu V., Hermansson K., Hilbrich L., Kaste M., Lu C., Machnig T., Pais P., Roberts R., Skvortsova V., Teal P., Toni D., Vander Maelen C., Voigt T., Weber M., Yoon B. W., Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. The New England Journal of Medicine 2008 359 12 1238 1251 2-s2.0-51449116270 10.1056/NEJMoa0805002
74. Bousser M. G., Amarenco P., Chamorro A., Fisher M., Ford I., Fox K. M., Hennerici M. G., Mattle H. P., Rothwell P. M., De Cordoüe A., Fratacci M. D., Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. The Lancet 2011 377 9782 2013 2022 2-s2.0-79958770159 10.1016/S0140-6736(11)60600-4
75. Geeganage C. M., Diener H.-C., Algra A., Chen C., Topol E. J., Dengler R., Markus H. S., Bath M. W., Bath P. M. W., Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke 2012 43 4 1058 1066 2-s2.0-84862800180 10.1161/STROKEAHA.111.637686
76. Benavente O. R., Hart R. G., McClure L. A., Szychowski J. M., Coffey C. S., Pearce L. A., Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. The New England Journal of Medicine 2012 367 9 817 825 2-s2.0-84865485153 10.1056/NEJMoa1204133
77. Holmes D. R., Kereiakes D. J., Kleiman N. S., Moliterno D. J., Patti G., Grines C. L., Combining antiplatelet and anticoagulant therapies. Journal of the American College of Cardiology 2009 54 2 95 109 2-s2.0-67649414486 10.1016/j.jacc.2009.03.044
78. Serebruany V. L., Steinhubl S. R., Berger P. B., Malinin A. I., Baggish J. S., Bhatt D. L., Topol E. J., Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. American Journal of Cardiology 2005 95 10 1218 1222 2-s2.0-18144373789 10.1016/j.amjcard.2005.01.049 (Pubitemid 40616424)
79. Sallustio F., Rotondo F., Legge S. D., Stanzione P., Cilostazol in the management of atherosclerosis. Current Vascular Pharmacology 2010 8 3 363 372 2-s2.0-77952896985 10.2174/157016110791112331
80. Kariyazono H., Nakamura K., Shinkawa T., Yamaguchi T., Sakata R., Yamada K., Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. Thrombosis Research 2001 101 6 445 453 2-s2.0-0035868374 10.1016/S0049-3848(00)00415-1 (Pubitemid 32367921)
81. Shinohara Y., Gotoh F., Tohgi H., Hirai S., Terashi A., Fukuuchi Y., Otomo E., Itoh E., Matsuda T., Sawada T., Yamaguchi T., Nishimaru K., Ohashi Y., Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients: subgroup analysis of the cilostazol stroke prevention study. Cerebrovascular Diseases 2008 26 1 63 70 2-s2.0-46449099089 10.1159/000135654 (Pubitemid 351931422)
82. Matsumoto M., Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atherosclerosis Supplements 2005 6 4 33 40 2-s2.0-32944473849 10.1016/j.atherosclerosissup.2005.09.003 (Pubitemid 43261538)
83. Shinoda-Tagawa T., Yamasaki Y., Yoshida S., Kajimoto Y., Tsujino T., Hakui N., Matsumoto M., Hori M., A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Diabetologia 2002 45 2 188 194 2-s2.0-0036190096 10.1007/s00125-001- 0740-2 (Pubitemid 34208380)
84. Sivenius J., Laakso M., Riekkinen P., Smets P., Lowenthal A., European Stroke Prevention Study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke. Stroke 1992 23 6 851 854 2-s2.0-0026766568
85. Grotta J. C., Norris J. W., Kamm B., Prevention of stroke with ticlopidine: who benefits most? Neurology 1992 42 1 111 115 2-s2.0-0026584514
86. Huang Y., Cheng Y., Wu J., Li Y., Xu E., Hong Z., Li Z., Zhang W., Ding M., Gao X., Fan D., Zeng J., Wong K., Lu C., Xiao J., Yao C., Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. The Lancet Neurology 2008 7 6 494 499 2-s2.0-43249105908 10.1016/S1474-4422(08)70094-2
87. Kamal A. K., Naqvi I., Husain M. R., Khealani B. A., Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database of Systematic Reviews 2011 1 CD008076 2-s2.0-79952268676
88. Uchiyama S., Ozaki Y., Satoh K., Kondo K., Nishimaru K., Effect of sarpogrelate, a 5-HT2A antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cerebrovascular Diseases 2007 24 2-3 264 270 2-s2.0-34548085420 10.1159/000105135 (Pubitemid 47295595)
89. Shinohara Y., Nishimaru K., Sawada T., Terashi A., Handa S., Hirai S., Hayashi K., Tohgi H., Fukuuchi Y., Uchiyama S., Yamaguchi T., Kobayashi S., Kondo K., Otomo E., Gotoh F., Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke 2008 39 6 1827 1833 2-s2.0-46249118961 10.1161/STROKEAHA.107.505131
90. Shinohara Y., Nishimaru K., Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes?: subgroup analysis from S-Access. Stroke 2009 40 8 2862 2865 2-s2.0-68749112764 10.1161/STROKEAHA.109.554246
91. Matías-Guiu J., Ferro J. M., Alvarez-Sabín J., Torres F., Jiménez M. D., Lago A., Melo T., Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP study: a randomized, double-blind, multicenter trial. Stroke 2003 34 4 840 848 2-s2.0-0037385048 10.1161/01.STR.0000063141.24491.50 (Pubitemid 36402947)
92. Costa J., Ferro J. M., Matias-Guiu J., Alvarez-Sabin J., Torres F., Triflusal for preventing serious vascular events in people at high risk. Cochrane Database of Systematic Reviews 2005 3 CD004296 2-s2.0-32944475708
93. Ringleb P. A., Bousser M.-G., Ford G., Bath P., Brainin M., Caso V., Cervera Á., Chamorro A., Cordonnier C., Csiba L., Davalos A., Diener H.-C., Ferro J., Hacke W., Hennerici M., Kaste M., Langhorne P., Lees K., Leys D., Lodder J., Markus H. S., Mas J.-L., Mattle H. P., Muir K., Norrving B., Obach V., Paolucci S., Ringelstein E. B., Schellinger P. D., Sivenius J., Skvortsova V., Sunnerhagen K. S., Thomassen L., Toni D., Von Kummer R., Wahlgren N. G., Walker M. F., Wardlaw J., Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular Diseases 2008 25 5 457 507 2-s2.0-48049093922 10.1159/000131083 (Pubitemid 351754643)
94. Taylor D. W., Barnett H. J. M., Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. The New
95. Dehaene I., D'Hooghe M., Joos F., Lanckneus M., Lecluyse A., Marchau M., Rocher A., Roussel J., Van Zandijke M., Dereume J., Hildebrand J., Ceusters W., De Reuck J., De Roose J., Decoo D., Derom D., Vakaet A., Carton H., Nevelsteen A., MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99) or with mild (0-29) carotid stenosis. The Lancet 1991 337 8752 1235 1243 2-s2.0-0025869608 10.1016/0140-6736(91)92916-P
96. Mayberg M. R., Wilson S. E., Yatsu F., Weiss D. G., Messina L., Hershey L. A., Colling C., Eskridge J., Deykin D., Winn H. R., Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. JAMA 1991 266 23 3289 3294 2-s2.0-0026350790 10.1001/jama.266.23.3289
97. Mas J. L., Chatellier G., Beyssen B., Branchereau A., Moulin T., Becquemin J. P., Larrue V., Lièvre M., Leys D., Bonneville J. F., Watelet J., Pruvo J. P., Albucher J. F., Viguier A., Piquet P., Garnier P., Viader F., Touzé E., Giroud M., Hosseini H., Pillet J. C., Favrole P., Neau J. P., Ducrocq X., Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. The New England Journal of Medicine 2006 355 16 1660 1671 2-s2.0-33750042277 10.1056/NEJMoa061752 (Pubitemid 44583956)
98. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006 368 9543 1239 1247 2-s2.0-39149103367 10.1016/S0140-6736(06) 69122-8 (Pubitemid 44485771)
99. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. The Lancet 2010 375 9719 985 997 2-s2.0-77955001180 10.1016/S0140-6736(10)60239-5
100. Ederle J., Bonati L. H., Dobson J., Featherstone R. L., Gaines P. A., Beard J. D., Venables G. S., Markus H. S., Clifton A., Sandercock P., Brown M. M., Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. The Lancet Neurology 2009 8 10 898 907 2-s2.0-69749113578 10.1016/S1474-4422(09)70228-5
101. Brott T. G., Hobson R. W., Howard G., Roubin G. S., Clark W. M., Brooks W., Mackey A., Hill M. D., Leimgruber P. P., Sheffet A. J., Howard V. J., Moore W. S., Voeks J. H., Hopkins L. N., Cutlip D. E., Cohen D. J., Popma J. J., Ferguson R. D., Cohen S. N., Blackshear J. L., Silver F. L., Mohr J. P., Lal B. K., Meschia J. F., Stenting versus endarterectomy for treatment of carotid-artery stenosis. The New England Journal of Medicine 2010 363 1 11 23 2-s2.0-77954204134 10.1056/NEJMoa0912321
102. Davis S. M., Donnan G. A., Carotid-artery stenting in stroke prevention. The New England Journal of Medicine 2010 363 1 80 82 2-s2.0-77954200392 10.1056/NEJMe1005220
103. Brown M. M., Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. The Lancet 2010 376 9746 1062 1073 2-s2.0-77957192193 10.1016/S0140- 6736(10)61009-4
104. Murad M. H., Shahrour A., Shah N. D., Montori V. M., Ricotta J. J., A systematic review and meta-analysis of randomized trials of carotid endarterectomy vs stenting. Journal of Vascular Surgery 2011 53 3 792 797 2-s2.0-79951857971 10.1016/j.jvs.2010.10.101
105. Meier P., Knapp G., Tamhane U., Chaturvedi S., Gurm H. S., Short term and intermediate term comparison of endarterectomy versus stenting for carotid artery stenosis: systematic review and meta-analysis of randomised controlled clinical trials. BMJ 2010 340, article c467 2-s2.0-77449148382 10.1136/bmj.c467
106. Eckstein H. H., Ringleb P., Allenberg J. R., Berger J., Fraedrich G., Hacke W., Hennerici M., Stingele R., Fiehler J., Zeumer H., Jansen O., Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. The Lancet Neurology 2008 7 10 893 902 2-s2.0-51449084646 10.1016/S1474-4422(08)70196-0
107. Steinbauer M. G. M., Pfister K., Greindl M., Schlachetzki F., Borisch I., Schuirer G., Feuerbach S., Kasprzak P. M., Alert for increased long-term follow-up after carotid artery stenting: results of a prospective, randomized, single-center trial of carotid artery stenting vs carotid endarterectomy. Journal of Vascular Surgery 2008 48 1 93 98 2-s2.0-45549110212 10.1016/j.jvs.2008.02.049
108. Rothwell P. M., Eliasziw M., Gutnikov S. A., Warlow C. P., Barnett H. J. M., Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. The Lancet 2004 363 9413 915 924 2-s2.0-1042300322 10.1016/S0140-6736(04)15785-1 (Pubitemid 38388324)
109. Rothwell P. M., Giles M. F., Chandratheva A., Marquardt L., Geraghty O., Redgrave J. N., Lovelock C. E., Binney L. E., Bull L. M., Cuthbertson F. C., Welch S. J., Bosch S., Carasco-Alexander F., Silver L. E., Gutnikov S. A., Mehta Z., Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. The Lancet 2007 370 9596 1432 1442 2-s2.0-35248869805 10.1016/S0140-6736(07)61448-2 (Pubitemid 47576154)
110. Sbarigia E., Toni D., Speziale F., Acconcia M. C., Fiorani P., Early carotid endarterectomy after ischemic stroke: the results of a prospective multicenter Italian study. European Journal of Vascular and Endovascular Surgery 2006 32 3 229 235 2-s2.0-33747047781 10.1016/j.ejvs.2006.03.016 (Pubitemid 44207907)
111. Ferrero E., Ferri M., Viazzo A., Gaggiano A., Ferrero M., Maggio D., Berardi G., Pecchio A., Piazza S., Cumbo P., Nessi F., Early carotid surgery in patients after acute ischemic stroke: is it safe? A retrospective analysis in a single center between early and delayed/deferred carotid surgery on 285 patients. Annals of Vascular Surgery 2010 24 7 890 899 2-s2.0-77956554871 10.1016/j.avsg.2010.03.014
112. Setacci C., de Donato G., Chisci E., Setacci F., Carotid artery stenting in recently symptomatic patients: a single center experience. Annals of Vascular Surgery 2010 24 4 474 479 2-s2.0-77951666373 10.1016/j.avsg.2009.07.022
113. Fridinger F. W., Jackson A. W., Andresen J., A comparison of results of a national cholesterol and blood pressure screening with the NHANES II Study: implications for further emphasis on reducing cardiovascular risk among Americans. Journal of Community Health 1992 17 4 247 257 2-s2.0-0026666137
114. Benson J., Britten N., Patients' decisions about whether or not to take antihypertensive drugs: qualitative study. British Medical Journal 2002 325 7369 873 876 2-s2.0-0037137059 (Pubitemid 35215261)
115. Gardner K., Chappie A., Chapple A., Barriers to referral in patients with angina: qualitative study. BMJ 1999 319 7207 418 421 2-s2.0-0033554151 (Pubitemid 29376242)
116. Burt V. L., Cutler J. A., Higgins M., Horan M. J., Labarthe D., Whelton P., Brown C., Roccella E. J., Trends in the prevalence, awareness, treatment, and control of hypertension in the adult us population: data from the health examination surveys, 1960 to 1991. Hypertension 1995 26 1 60 69 2-s2.0-0029920672
117. DeBusk R. F., MULTIFIT: a new approach to risk factor modification. Cardiology Clinics 1996 14 1 143 157 2-s2.0-0030023784
118. Mouradian M. S., Majumdar S. R., Senthilselvan A., Khan K., Shuaib A., How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack? Stroke 2002 33 6 1656 1659 2-s2.0-0036284168 10.1161/01.STR.0000017877.62543.14 (Pubitemid 34619974)
119. Nolan R. P., Liu S., Shoemaker J. K., Hachinski V., Lynn H., Mikulis D. J., Wennberg R. A., Lum-Kwong M. M., Zbib A., Therapeutic benefit of internet-based lifestyle counselling for hypertension. Canadian Journal of Cardiology 2012 28 3 390 396 2-s2.0-84860920893 10.1016/j.cjca.2012.02.012
120. McGrath E. R., Glynn L. G., Murphy A. W., Conghaile A. O., Canavan M., Reid C., Moloney B., O'Donnell M. J., Preventing cardiovascular disease in primary care: role of a national risk factor management program. American Heart Journal 2012 163 4 714 719 2-s2.0-0035806726 10.1016/j.ahj.2012.01.027